Rights Issue Shortfall

Friday, 30 August 2019

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine
company, advises that its partially underwritten non-renounceable rights issue of one New Share
for every six shares held, at an issue price of $0.08 closed as scheduled on 27 August 2019.